"Lilly trades at $948.45 as of writing. Our 24/7 Wall St. price target is $1,085 over the next 12 months, implying roughly 14.3% upside. The recommendation is buy with a confidence level of 70%. Management raised guidance, Mounjaro is now the best-selling drug globally, and Foundayo opened a new oral-GLP-1 chapter."
"Revenue came in at $19.80 billion, up 55.5% year over year, and non-GAAP EPS of $8.55 beat consensus by $6.79. Mounjaro delivered $8.66 billion, overtaking Merck ( NYSE:MRK)'s Keytruda as the world's top-selling drug. Shares jumped 9.8% on the report and added another 4.32% in the week since."
"The bull case is straightforward. Cantor Fitzgerald lifted its target to $1,230 with an Overweight rating, citing Mounjaro demand and Foundayo momentum. Foundayo, the only oral GLP-1 dosable any time without food or water, reached 20,000 patients with 80% of scripts from new-to-class users. Barclays has raised the price target to $1,400 with an Overweight rating."
"The bear case starts with concentration. Mounjaro plus Zepbound generated roughly $12.8 billion of the $19.80 billion Q1 total, and pricing is eroding. Realized prices fell 13%, with full-ye"
Eli Lilly trades near $948 and has a 12-month target of $1,085, implying about 14% upside. The company reported Q1 2026 revenue of $19.80 billion, up 55.5% year over year, and non-GAAP EPS of $8.55, beating consensus. Mounjaro generated $8.66 billion and became the top-selling drug globally, driving share gains. Bulls point to continued demand for Mounjaro and rapid adoption of Foundayo, an oral GLP-1, with 20,000 patients and 80% of scripts from new-to-class users. Retatrutide Phase 3 results show substantial weight loss, and international revenue is growing 81%. Risks include revenue concentration in Mounjaro and Zepbound and declining realized prices, alongside potential execution and competitive pressures.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]